Dose-dependent increase in the QTc interval in aripiprazole treatment after risperidone

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 2, 2011, Pages 643-644

  Suzuki, Yutaro ^a   Ono, Shin ^a   Fukui, Naoki ^a   Sugai, Takuro ^a   Watanabe, Junzo ^a   Tsuneyama, Nobuto ^a   Someya, Toshiyuki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PROLACTIN; RISPERIDONE;

ADULT; CASE REPORT; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; HUMAN; LETTER; MALE; PROLACTIN BLOOD LEVEL; QT INTERVAL; QT PROLONGATION; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; ARRHYTHMIAS, CARDIAC; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HUMANS; MALE; PIPERAZINES; QUINOLONES; RISPERIDONE;

EID: 79952902068     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.10.024     Document Type: Letter

References (4)

1. Glassman A.H., Bigger J.T. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001, 158:1774-1782.
2. Pigott T.A., Carson W.H., Saha A.R., Torbeyns A.F., Stock E.G., Ingenito G.G. Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003, 64:1048-1056.
3. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003, 60:681-690.
4. Stip E., Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther 2010, 32(Suppl 1):S3-S20.